Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Intercept Pharmaceuticals Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Intercept Pharmaceuticals Inc market cap is $794.69M.
What is the 52-week high for Intercept Pharmaceuticals Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Intercept Pharmaceuticals Inc 52 week high is $21.86 as of September 23, 2025.
What is the 52-week low for Intercept Pharmaceuticals Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Intercept Pharmaceuticals Inc 52 week low is $8.82 as of September 23, 2025.
What is Intercept Pharmaceuticals Inc stock price today?
Intercept Pharmaceuticals Inc stock price today is $19.00.
What was Intercept Pharmaceuticals Inc stock price yesterday?
Intercept Pharmaceuticals Inc stock price yesterday was $18.96.
What is the PE ratio of Intercept Pharmaceuticals Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Intercept Pharmaceuticals Inc’s P/E ratio is -13.58.
What is the Price-to-Book ratio of Intercept Pharmaceuticals Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Intercept Pharmaceuticals Inc P/B ratio is 11.0574.
What is Intercept Pharmaceuticals Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Intercept Pharmaceuticals Inc's EBITDA is -12.32.
What is the 50-day moving average of Intercept Pharmaceuticals Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Intercept Pharmaceuticals Inc 50-day moving average is $16.96.
